David J. Matthews & Mary E. Gerritsen 
Targeting Protein Kinases for Cancer Therapy 

An expert guide to targeting protein kinases in cancer
therapy

Research has shown that protein kinases can instigate the
formation and spread of cancer when they transmit faulty signals
inside cells. Because of this fact, pharmaceutical scientists have
targeted kinases for intensive study, and have been working to
develop medicinal roadblocks to sever their malignant means of
communication.

Complete with full-color presentations, Targeting Protein
Kinases for Cancer Therapy defines the structural features of
protein kinases and examines their cellular functions. Combining
kinase biology with chemistry and pharmacology applications, this
book enlists emerging data to drive the discovery of new
cancer-fighting drugs. Valuable information includes:

* Comprehensive overviews of the major kinase families involved in
oncology, integrating protein structure and function, and providing
important tools to assist pharmaceutical researchers to understand
and work in this dynamic area of cancer drug research

* Focus on small molecule inhibitors as well as other therapeutic
modalities

* Discussion of kinase inhibitors that have entered clinical
trials for the treatment of cancer, with an emphasis on molecules
that have progressed to late stage clinical trials and, in a few
cases, to market

Providing a platform for further study, this important work
reviews both the successes and challenges of kinase inhibitor
therapy, and provides insight into future directions in the war
against cancer.

Tentang Penulis

DAVID J. MATTHEWS is Executive Director of Oncology
Discovery at Exelixis, where he is responsible for cancer drug
discovery. For more than fifteen years, Dr. Matthews has been
involved in drug discovery projects in industry, with particular
focus on small molecule inhibitors. He has twenty scientific
publications and multiple patents to his credit.

MARY E. GERRITSEN is Vice President of Molecular and
Cellular Pharmacology at Exelixis, where she is in charge of
cell-based screening in preclinical research and of biomarker
studies for clinical development compounds in Phase I and II
studies. Her prior industry experience includes positions at
Genentech, Bayer and Millennium Pharmaceuticals. She has authored
more than one hundred peer-reviewed articles and twenty-six book
chapters and is an inventor on forty-two issued patents.